Significance of the TEL-AML fusion gene in childhood AML

TO THE EDITOR
We agree with Seeger and colleagues that large prospective studies of consecutive newly diagnosed ALL cases are needed to definitively determine the prognostic significance of the TEL-AML1 fusion. While Seeger and colleagues have now confirmed their previous report 1 of a high frequency of TEL-AML1 positivity among cases of B cell precursor ALL in first relapse, they also note the wide variation in frequencies reported in the literature (3-28%). In our analysis of relapsed childhood ALL cases, 10.2% (five of 49) expressed TEL-AML1. 2 Even if we limit our analysis to cases with a B cell precursor phenotype, the frequency only increases to 10.8% (five of 46 cases).
We have previously reported a favorable prognosis associated with the TEL-AML1 fusion in ALL cases treated at our center. In a study of ALL cases treated on the St Jude Total XII protocol, we molecularly analyzed 170 of 188 cases (90%), including 138 of 146 (95%) of B precursor ALL. 3 Only two relapses were observed among 30 TEL-AML1-positive cases. 3 In a recent update, we have demonstrated that the 10-year cumulative incidence of relapse was only 9 ± 5% for TEL-AML1-positive cases, with all relapses occurring more than 3 years from diagnosis. 2, 4 Notwithstanding the excellent treatment results for TEL-AML1-positive cases in our and other studies, 5, 6 we must remember that treatment efficacy is the important prognostic factor that can alter the clinical significance of genetic alterations. treated with a non-intensive antimetabolite-based regimen had a 5-year disease-free survival rate of only 55 ± 15%, compared to a rate of 100% in those treated on a more intensive contemporary protocol. 7 We suggest that all newly diagnosed ALL cases be screened for the TEL-AML1 fusion and that these patients receive risk-adapted therapy and suitable monitoring. In our current ALL trial, TEL-AML1-positive patients are provisionally assigned to the low-risk arm at diagnosis and receive intensified antimetabolite-based therapy. However, patients with a slow early response to therapy or with detectable minimal residual disease (Ͼ1 × 10
) at the end of induction are assigned to the more intensive standard-risk therapeutic arm. Future studies will focus on defining the optimal therapy for TEL-AML1 leukemia to further improve cure rates and decrease treatment-related morbidity.
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Megakaryocyte growth factors and acute myeloid leukemia
TO THE EDITOR I read with interest the review paper by Hofmann and colleagues 1 on the potential role of megakaryocytic growth factors in patients with thrombocytopenia. Overall, the authors nicely summarize a very rapidly growing literature in the field, and bring several important questions to the fore. However, I believe the wrong impression is left in their discussion of the effects of thrombopoietin in patients undergoing standard dose chemotherapy for acute myelogenous leukemia. On this topic Hofmann and colleagues cite an abstract submitted to the 1996 meeting of the American Society of Hematology, 2 and suggest that thrombopoietin had a favorable effect on platelet recovery (22 days to unsupported platelet count у20 000/l in the two thrombopoietin treatment groups vs 27 days in the placebo group). Although the printed abstract clearly provides these data, when the study group had doubled in size by the time the paper was presented in December 1996, the favorable differences between the treatment and placebo groups disappeared, and the lead author, Dr Archimbaud, concluded there was no effect of thrombopoietin when given to their patients Clinical use of thrombopoietin TO THE EDITOR Thank you very much for giving us the opportunity to respond to the letter to the editor by Dr K Kaushansky 1 referring to our review 'Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies' 2 with the implication that 'the wrong impression is left in [our] discussion of the effects of thrombopoietin in patients undergoing standard-dose chemotherapy for acute myelogenous leukemia'.
In our review, which is based on a lecture delivered in July 1997 at the XIX Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (Mannheim, Germany), we describe a multicenter study of PEG-rHuMGDF in patients with de novo AML, and cite the abstract that was submitted to -and presented at -the 1996 meeting of the American Society of Hematology. What is described in the review is the comparison between the MGDF and placebo groups in terms of platelet recovery times, incidence of thrombocytosis, prolonged elevations of platelet counts, days to neutrophil recovery, RBC transfusion requirements, incidence of thrombotic events and remission rates as provided in this abstract. Already at this ASH meeting, the lead author Dr Archimbaud showed on the basis of a somewhat larger number of patients that the difference in thrombocytopenia duration between the placebo and MGDF
